Pure D2CUS

Medifast benchmarks

MED · United States

How Medifast runs its business, at a glance: $300M in revenue in the last 12 months (-30.3%), compared with 32 other pure D2C brands on growth, margins and marketing. 17 fiscal years since 2009 and 65 quarters from SEC filings.

Compare your brandSee peersFull history

Revenue, last 12 months$300M-30.3% on the year before · #107 of 180 by revenue
Growth-30.3%Below the pure D2C median
Gross margin69.2%Above the pure D2C median
Marketing0.4%Spends less than the pure D2C median
Operating margin-11.6%Below the pure D2C median

Operating scorecard

The numbers that show how Medifast runs: what it keeps from each sale, what it spends to win customers, and what is left. Each card shows the trend and where Medifast ranks.

Revenue, last 12 months

$300M-30.3% on a year earlier

In USD, as reported, 12 months to 2026-09.

2016: $275M2017: $302M2018: $501M2019: $714M2020: $935M2021: $1.53B2022: $1.6B2023: $1.07B2024: $602M2025: $386M
20162025

#107 by revenue of 180 brands in the benchmark.

Revenue growth

-30.3%▲ 5.7 pts vs 2025

Revenue against the year before

2016: +0.6%2017: +9.8% (peer median +15.6%)2018: +66.1% (peer median +20.7%)2019: +42.4% (peer median +26.4%)2020: +31% (peer median +25.1%)2021: +63.2% (peer median +36.1%)2022: +4.8% (peer median +15.1%)2023: -32.9% (peer median +5.2%)2024: -43.8% (peer median +1.2%)2025: -36% (peer median +3.1%)
2016peer median2025

Below the pure D2C median (+4.6%). Grows faster than 5% of all 174 brands.

Gross margin

69.2%▼ 2.1 pts vs 2025

Left of each sale after product and delivery costs

2016: 74.9% (peer median 56.1%)2017: 75.5% (peer median 53.3%)2018: 75.8% (peer median 58%)2019: 75.2% (peer median 55.1%)2020: 74.6% (peer median 58.5%)2021: 73.9% (peer median 59.4%)2022: 71.3% (peer median 54.3%)2023: 72.4% (peer median 56.1%)2024: 73.8% (peer median 61.4%)2025: 71.3% (peer median 57.5%)
2016peer median2025

Above the pure D2C median (58.4%). Higher margin than 86% of all 169 brands.

Marketing spend

0.4%▼ 1.6 pts vs 2025

Share of revenue spent on marketing and advertising

2016: 3.4% (peer median 14.9%)2017: 2.6% (peer median 16.4%)2018: 1.2% (peer median 19.3%)2019: 0.7% (peer median 19.4%)2020: 0.5% (peer median 18.1%)2021: 0.1% (peer median 21.8%)2022: 0.1% (peer median 19.8%)2023: 0.3% (peer median 20.7%)2024: 2.3% (peer median 18.8%)2025: 1.9% (peer median 18.7%)
2016peer median2025

Spends less than the pure D2C median (18.9%). Spends more than 1% of all 144 brands.

Headroom

68.8%▼ 0.5 pts vs 2025

Gross margin minus marketing: what is left for the team, rent and profit

2016: 71.5% (peer median 33.6%)2017: 73% (peer median 37.2%)2018: 74.6% (peer median 36.2%)2019: 74.5% (peer median 28.5%)2020: 74.2% (peer median 33.9%)2021: 73.8% (peer median 32.1%)2022: 71.2% (peer median 30.9%)2023: 72.1% (peer median 31.8%)2024: 71.5% (peer median 35.3%)2025: 69.4% (peer median 36.5%)
2016peer median2025

Above the pure D2C median (37.1%). More headroom than 99% of all 137 brands.

Operating margin

-11.6%▼ 7.9 pts vs 2025

Profit from operations, before interest and tax

2016: +9.8% (peer median +7.8%)2017: +13.1% (peer median -1.5%)2018: +13.8% (peer median -1.5%)2019: +12.8% (peer median -0.3%)2020: +14.4% (peer median -0.6%)2021: +14.2% (peer median +2.9%)2022: +11.6% (peer median -6.9%)2023: +11.8% (peer median -5.6%)2024: +0.5% (peer median -4%)2025: -3.7% (peer median -2.2%)
2016peer median2025

Below the pure D2C median (-2.8%). More profitable than 16% of all 178 brands.

Medifast: 12 months to 2026-09. Trend lines: the last 10 fiscal years, dashed line the median pure D2C brand in the same year. Bars: where Medifast sits among all 180 brands, from lowest to highest.

Where every 100 of revenue goes

For every 100 Medifast takes in: what the products cost to make and deliver, what goes to marketing, what runs the company, and what is left as profit.

Product and deliveryMarketingTeam, rent and other costsOperating profitLoss (costs above revenue)

Medifast12 months to 2026-09
MedifastFY 2010
Pure D2C median32 brands
All brands median180 brands

Medians are worked out line by line, so their parts can add up to slightly more or less than 100. Product and delivery is revenue minus gross profit; how much shipping sits there differs by company.

Compare your brand

Type in your own numbers to see where you stand against Medifast, the median pure D2C brand, and all 180 brands.

Your last 12 months, as % of revenue. Nothing you type leaves this page.

Your numbers against Medifast and the pure D2C median
MetricYouMedifastGapPure D2CmedianAmong all brands
Revenue growth–-30.3%–+4.6%–
Gross margin–69.2%–58.4%–
Marketing spend–0.4%–18.9%–
Headroom–68.8%–37.1%–
Operating margin–-11.6%–-2.8%–

Medifast and its peers

Pure D2C brands of a similar size, side by side.

All pure D2C brands
Medifast and the closest pure D2C brands by revenue
BrandRevenueGrowthGross marginMarketingHeadroomOp. margin
Rent the RunwayRENT · US $367M+21.2%74.7%7.2%67.5%-12.3%
ThredUpTDUP · US $340M+14.1%79.2%18.9%60.3%-7.2%
MedifastMED · US $300M-30.3%69.2%0.4%68.8%-11.6%
Marley Spoon GroupMS1 · Europe €238M-22.5%51.6%14.5%37.1%-3%
Naked WinesWINE · Europe £199M-20.4%19.9%3.8%16%-2.6%
Lulu's Fashion LoungeLVLU · US $247M-13.5%45.8%24.2%21.7%-3.5%
ZEAL NetworkTIMA · Europe €218M+16.1%–31.4%–+27.5%
BeachbodyBODI · US $205M-27.6%72.4%31.2%41.1%+7%
Pure D2C median32 brands+4.6%58.4%18.9%37.1%-2.8%

The 7 pure D2C brands closest to Medifast in revenue. Green: above the median, grey: below. Revenue in each company's own currency.

Revenue by year

Every fiscal year on record, in USD. Point at a bar for growth and margins.

FY 2009: revenue $170M, gross margin 73.3%, operating margin +10.9% 2009FY 2010: revenue $258M, +51.7% on a year earlier, gross margin 74.7%, marketing 8.9%, operating margin +12.3% FY 2011: revenue $298M, +15.8% on a year earlier, gross margin 75.3%, marketing 9.1%, operating margin +9.2% 2011FY 2012: revenue $319M, +6.8% on a year earlier, gross margin 74.1%, marketing 8.2%, operating margin +8.5% FY 2013: revenue $324M, +1.7% on a year earlier, gross margin 74.2%, marketing 6.5%, operating margin +11.9% 2013FY 2014: revenue $285M, -12% on a year earlier, gross margin 73.3%, marketing 6%, operating margin +10.6% FY 2015: revenue $273M, -4.4% on a year earlier, gross margin 73.8%, marketing 5.6%, operating margin +10.5% 2015FY 2016: revenue $275M, +0.6% on a year earlier, gross margin 74.9%, marketing 3.4%, operating margin +9.8% FY 2017: revenue $302M, +9.8% on a year earlier, gross margin 75.5%, marketing 2.6%, operating margin +13.1% 2017FY 2018: revenue $501M, +66.1% on a year earlier, gross margin 75.8%, marketing 1.2%, operating margin +13.8% FY 2019: revenue $714M, +42.4% on a year earlier, gross margin 75.2%, marketing 0.7%, operating margin +12.8% 2019FY 2020: revenue $935M, +31% on a year earlier, gross margin 74.6%, marketing 0.5%, operating margin +14.4% FY 2021: revenue $1.53B, +63.2% on a year earlier, gross margin 73.9%, marketing 0.1%, operating margin +14.2% 2021FY 2022: revenue $1.6B, +4.8% on a year earlier, gross margin 71.3%, marketing 0.1%, operating margin +11.6% FY 2023: revenue $1.07B, -32.9% on a year earlier, gross margin 72.4%, marketing 0.3%, operating margin +11.8% 2023FY 2024: revenue $602M, -43.8% on a year earlier, gross margin 73.8%, marketing 2.3%, operating margin +0.5% FY 2025: revenue $386M, -36% on a year earlier, gross margin 71.3%, marketing 1.9%, operating margin -3.7% 2025
RevenueGross margin (0–100% scale)Marketing (0–100% scale)
Medifast by fiscal year
Fiscal yearRevenueGrowthGross marginMarketingOp. marginNet marginSource
2025ends 2025-12-31 $386M-36%71.3% 1.9%-3.7%-4.9% 10-K filed 2026-02-17
2024ends 2024-12-31 $602M-43.8%73.8% 2.3%+0.5%+0.3% 10-K filed 2026-02-17
2023ends 2023-12-31 $1.07B-32.9%72.4% 0.3%+11.8%+9.2% 10-K filed 2026-02-17
2022ends 2022-12-31 $1.6B+4.8%71.3% 0.1%+11.6%+9% 10-K filed 2025-02-18
2021ends 2021-12-31 $1.53B+63.2%73.9% 0.1%+14.2%+10.7% 10-K filed 2024-02-20
2020ends 2020-12-31 $935M+31%74.6% 0.5%+14.4%+11% 10-K filed 2021-02-26
2019ends 2019-12-31 $714M+42.4%75.2% 0.7%+12.8%+10.9% 10-K filed 2021-02-26
2018ends 2018-12-31 $501M+66.1%75.8% 1.2%+13.8%+11.1% 10-K filed 2021-02-26
2017ends 2017-12-31 $302M+9.8%75.5% 2.6%+13.1%+9.2% 10-K filed 2020-03-02
2016ends 2016-12-31 $275M+0.6%74.9% 3.4%+9.8%+6.5% 10-K filed 2019-03-01
2015ends 2015-12-31 $273M-4.4%73.8% 5.6%+10.5%+7.4% 10-K filed 2018-03-16
2014ends 2014-12-31 $285M-12%73.3% 6%+10.6%+4.6% 10-K filed 2017-03-16
2013ends 2013-12-31 $324M+1.7%74.2% 6.5%+11.9%+7.4% 10-K filed 2016-03-15
2012ends 2012-12-31 $319M+6.8%74.1% 8.2%+8.5%+5% 10-K filed 2015-03-16
2011ends 2011-12-31 $298M+15.8%75.3% 9.1%+9.2%+6.2% 10-K filed 2014-03-17
2010ends 2010-12-31 $258M+51.7%74.7% 8.9%+12.3%+7.6% 10-K filed 2013-03-15
2009ends 2009-12-31 $170M–73.3% –+10.9%+6.7% 10-K filed 2012-03-15

Revenue and margins by quarter

The last 16 calendar quarters. Most companies only report Q4 inside their annual report, so Q4 is the full year minus the first three quarters.

Q4 2022: revenue $337M, -10.7% on a year earlier, gross margin 69.3%, operating margin +9.7% Q1 2023: revenue $349M, -16.4% on a year earlier, gross margin 70.6%, operating margin +15.3% Q1 2023Q2 2023: revenue $296M, -34.7% on a year earlier, gross margin 71.1%, operating margin +13.1% Q3 2023: revenue $236M, -39.6% on a year earlier, gross margin 75.2%, marketing 0.6%, operating margin +10.8% Q3 2023Q4 2023: revenue $191M, -43.4% on a year earlier, gross margin 74%, operating margin +4.5% Q1 2024: revenue $175M, -49.9% on a year earlier, gross margin 72.8%, marketing 1.4%, operating margin +4.5% Q1 2024Q2 2024: revenue $169M, -43.1% on a year earlier, gross margin 73.2%, marketing 1.7%, operating margin -4.7% Q3 2024: revenue $140M, -40.6% on a year earlier, gross margin 75.4%, marketing 3.3%, operating margin +1.5% Q3 2024Q4 2024: revenue $119M, -37.7% on a year earlier, gross margin 74.1%, marketing 3.5%, operating margin +0.6% Q1 2025: revenue $116M, -33.8% on a year earlier, gross margin 72.8%, marketing 4%, operating margin -1.1% Q1 2025Q2 2025: revenue $106M, -37.4% on a year earlier, gross margin 72.6%, marketing 1.5%, operating margin -1% Q3 2025: revenue $89M, -36.2% on a year earlier, gross margin 69.5%, marketing 0.8%, operating margin -4.6% Q3 2025Q4 2025: revenue $75M, -36.9% on a year earlier, gross margin 69.4%, marketing 0.8%, operating margin -10.4% Q1 2026: revenue $76M, -34.3% on a year earlier, gross margin 68.1%, marketing 0.3%, operating margin -4.3% Q1 2026Q2 2026: revenue $76M, -27.6% on a year earlier, gross margin 69.9%, marketing 0.3%, operating margin -5.7% Q3 2026: revenue $72M, -19.4% on a year earlier, gross margin 69.5%, marketing 0.1%, operating margin -26.9% Q3 2026
RevenueGross margin (0–100% scale)Marketing (0–100% scale)
All 65 quarters
Medifast by quarter
QuarterRevenuevs year earlierGross marginMarketingOp. marginSource
Q3 2026 $72M-19.4%69.5% 0.1%-26.9% 10-Q filed 2026-10-26
Q2 2026 $76M-27.6%69.9% 0.3%-5.7% 10-Q filed 2026-08-03
Q1 2026 $76M-34.3%68.1% 0.3%-4.3% 10-Q filed 2026-05-04
Q4 2025full year minus Q1–Q3 $75M-36.9%69.4% 0.8%-10.4% 10-K filed 2026-02-17
Q3 2025 $89M-36.2%69.5% 0.8%-4.6% 10-Q filed 2026-10-26
Q2 2025 $106M-37.4%72.6% 1.5%-1% 10-Q filed 2026-08-03
Q1 2025 $116M-33.8%72.8% 4%-1.1% 10-Q filed 2026-05-04
Q4 2024full year minus Q1–Q3 $119M-37.7%74.1% 3.5%+0.6% 10-K filed 2026-02-17
Q3 2024 $140M-40.6%75.4% 3.3%+1.5% 10-Q filed 2025-11-03
Q2 2024 $169M-43.1%73.2% 1.7%-4.7% 10-Q filed 2025-08-04
Q1 2024 $175M-49.9%72.8% 1.4%+4.5% 10-Q filed 2025-04-28
Q4 2023full year minus Q1–Q3 $191M-43.4%74% –+4.5% 10-K filed 2026-02-17
Q3 2023 $236M-39.6%75.2% 0.6%+10.8% 10-Q filed 2024-11-04
Q2 2023 $296M-34.7%71.1% –+13.1% 10-Q filed 2024-08-05
Q1 2023 $349M-16.4%70.6% –+15.3% 10-Q filed 2024-04-29
Q4 2022full year minus Q1–Q3 $337M-10.7%69.3% –+9.7% 10-K filed 2025-02-18
Q3 2022 $390M-5.6%72.5% –+12.3% 10-Q filed 2022-11-03
Q2 2022 $453M+15%71% –+10.8% 10-Q filed 2022-08-03
Q1 2022 $418M+22.6%72.4% –+13.2% 10-Q filed 2022-05-02
Q4 2021full year minus Q1–Q3 $378M+42.6%73.7% –+12.4% 10-K filed 2024-02-20
Q3 2021 $413M+52.3%74.3% –+13.3% 10-Q filed 2022-11-03
Q2 2021 $394M+79.2%74.5% –+15.6% 10-Q filed 2022-08-03
Q1 2021 $341M+90.9%73% –+15.5% 10-Q filed 2022-05-02
Q4 2020 $265M+55.3%75.2% –– 10-K filed 2021-02-26
Q3 2020 $271M+42.8%75.2% –+16.4% 10-Q filed 2021-11-04
Q2 2020 $220M+17.6%72.4% –+12.8% 10-Q filed 2021-08-04
Q1 2020 $178M+7.6%75.8% –+13.2% 10-Q filed 2021-05-04
Q4 2019 $171M+17%75.1% –– 10-K filed 2021-02-26
Q3 2019 $190M+36.5%75.2% –+10.7% 10-K filed 2021-02-26
Q2 2019 $187M+59.5%75.2% –+14.6% 10-K filed 2021-02-26
Q1 2019 $166M+68.2%75.4% –+14.9% 10-K filed 2021-02-26
Q4 2018 $146M+87%74.8% –– 10-K filed 2020-03-02
Q3 2018 $139M+80.3%77% –+12.5% 10-K filed 2020-03-02
Q2 2018 $117M+54.9%75.7% –+14.6% 10-K filed 2020-03-02
Q1 2018 $99M+39.6%75.9% –+14.9% 10-K filed 2020-03-02
Q4 2017 $78M+24.9%75.8% –– 10-K filed 2019-03-01
Q3 2017 $77M+12.6%75.4% –+13.2% 10-K filed 2019-03-01
Q2 2017 $76M+6.4%76.1% –+14.9% 10-K filed 2019-03-01
Q1 2017 $71M-2.4%74.9% –+12.2% 10-K filed 2019-03-01
Q4 2016 $62M+1.9%75.4% –– 10-K filed 2018-03-16
Q3 2016 $69M+4%76.1% –+13.1% 10-K filed 2018-03-16
Q2 2016 $71M-1.4%74.8% –+7.1% 10-K filed 2018-03-16
Q1 2016 $72M-1.4%73.5% –+8.7% 10-K filed 2018-03-16
Q4 2015 $61M-1.6%73.8% –– 10-K filed 2017-03-16
Q3 2015 $66M-4.5%74.6% –+12.1% 10-K filed 2017-03-16
Q2 2015 $72M-3.4%73.7% –+12% 10-K filed 2017-03-16
Q1 2015 $73M-7.4%73.3% –+8.9% 10-K filed 2017-03-16
Q4 2014full year minus Q1–Q3 $62M+40.1%72.2% –+6.7% 10-K filed 2017-03-16
Q3 2014 $69M-20.2%73.5% –+9.5% 10-Q filed 2015-11-09
Q2 2014 $75M-23%74.4% –+13.2% 10-Q filed 2015-08-10
Q1 2014 $79M-17.5%73.1% –+12.1% 10-Q filed 2015-05-11
Q4 2013full year minus Q1–Q3 $44M-1.4%68.3% –+26.6% 10-K filed 2016-03-15
Q3 2013 $86M-4.9%75% –+8.5% 10-Q filed 2014-11-10
Q2 2013 $97M+3.7%75.1% –+11% 10-Q filed 2014-08-11
Q1 2013 $96M+8%75.4% –+8.9% 10-Q filed 2014-05-12
Q4 2012full year minus Q1–Q3 $45M-35.2%68% –+16.6% 10-K filed 2015-03-16
Q3 2012 $91M+19.6%75.1% –+9.8% 10-Q filed 2013-11-12
Q2 2012 $94M+19.6%75% –+4.9% 10-Q filed 2013-08-09
Q1 2012 $89M+19.7%75.1% –+6.9% 10-Q filed 2013-05-10
Q4 2011full year minus Q1–Q3 $70M–75.2% –+2.2% 10-K filed 2014-03-17
Q3 2011 $76M+13.1%74.2% –+8.8% 10-Q filed 2012-11-09
Q2 2011 $78M+17.4%75.4% –+11.6% 10-Q filed 2012-08-09
Q1 2011 $74M–76.3% –+13.6% 10-Q filed 2012-05-10
Q3 2010 $67M–75% –+13.4% 10-Q filed 2011-11-09
Q2 2010 $67M–74.2% –+13.9% 10-Q filed 2011-08-09

Sources

Every figure is from Medifast's SEC filings (XBRL data in its 10-K and 10-Q reports): all filings on SEC EDGAR. Each row above links to the filing it came from.

Marketing is whatever the company reports as marketing, advertising or selling and marketing, so definitions differ between companies. Rankings compare each brand's latest 12 months (US) or latest fiscal year (Europe).

All D2C benchmarks

From the team behind this directory

You've seen how Medifast does it. Now see how yours compares.

Bratrax connects to your Shopify store and ad accounts and shows you the numbers that decide whether you're making money: profit after ad spend and product costs, which channels bring customers who come back, and where your next dollar should go.

$1 first month · then $99/month flat · no contract

  • Revenue, ad spend, MER and profit for the whole store on one screen
  • Every order traced back to the campaign that brought it
  • New vs. returning customers, cohorts and lifetime value
  • Email campaigns and flows, with the revenue they drove
  • Ask questions in plain English with your own Claude